Prognostic value of immunohistochemical expression of HER-2/neu in patients with lung carcinoma
Journal
Radiology and oncology
Date Issued
2008
Author(s)
Ilievska Poposka, Biljana
Stefanovski, Tome
DOI
doi:10.2478/v10019-008-0014-4
Abstract
Background. The amplification and the overexpression of the Her-2/neu gene have been shown in certain
human tumours and are postulated to be important in human carcinogenesis. In this study we evaluated
the expression of HER-2/neu gene in patients with lung carcinoma (LC) and assessed its prognostic significance.
Patients and methods. HER-2/neu expression was determined in 127 LC patients using immunohistochemistry (IHC) performed on paraffin-embedded section – Hercep TestTM (DAKO).
Results. The overall HER-2/neu expression was seen in 36 (28.35%) of 127 LC patients. According to the
histological type, HER-2/neu overexpression was detected in 12 patients with adenocarcinomas (60%), in
19 patients with squamous cell carcinomas (31.14%), in 4 patients with small cell-lung carcinomas (10%)
and in 1 patient with other carcinomas (16.66%). Only in patients with small cell-lung carcinomas HER-2/
neu overexpression was in correlation with the stage of the disease (p<0.001). The patients with HER-2/neu
positive expression were associated with a significantly shorter survival compared with those who were
HER-2/neu negative (log rank, p<0.002).
Conclusions. These observations suggest that HER-2/neu positivity may serve as a prognostic indicator
in patients with LC. HER-2/neu plays a role in identifying patients at risk for the shortened survival, who
may benefit from a more aggressive therapy.
Key words: HER-2/neu, lung cancer; immunohistochemisty; survival
human tumours and are postulated to be important in human carcinogenesis. In this study we evaluated
the expression of HER-2/neu gene in patients with lung carcinoma (LC) and assessed its prognostic significance.
Patients and methods. HER-2/neu expression was determined in 127 LC patients using immunohistochemistry (IHC) performed on paraffin-embedded section – Hercep TestTM (DAKO).
Results. The overall HER-2/neu expression was seen in 36 (28.35%) of 127 LC patients. According to the
histological type, HER-2/neu overexpression was detected in 12 patients with adenocarcinomas (60%), in
19 patients with squamous cell carcinomas (31.14%), in 4 patients with small cell-lung carcinomas (10%)
and in 1 patient with other carcinomas (16.66%). Only in patients with small cell-lung carcinomas HER-2/
neu overexpression was in correlation with the stage of the disease (p<0.001). The patients with HER-2/neu
positive expression were associated with a significantly shorter survival compared with those who were
HER-2/neu negative (log rank, p<0.002).
Conclusions. These observations suggest that HER-2/neu positivity may serve as a prognostic indicator
in patients with LC. HER-2/neu plays a role in identifying patients at risk for the shortened survival, who
may benefit from a more aggressive therapy.
Key words: HER-2/neu, lung cancer; immunohistochemisty; survival
File(s)![Thumbnail Image]()
Loading...
Name
[Radiology and Oncology] Prognostic value of immunohistochemical expression of HER-2neu in patients with lung carcinoma.pdf
Size
219.72 KB
Format
Adobe PDF
Checksum
(MD5):4a26fa4701fca8c9a16324b946a502d8